HCM
CBIO

Heights Capital Management’s Crescent Biopharma CBIO Stock Holding History

Heights Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-264,000
Closed -$3.13M – 271
2025
Q4 		$3.13M Buy
+264,000
New +$3.36M 1.12% 20

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Heights Capital Management's CBIO Position: Q1 2026 in Review

Heights Capital Management sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 264,000 shares — an estimated $3.13M sold.

Heights Capital Management first reported a position in CBIO in Q4 2025 and held it in 1 quarter. The position peaked at $3.13M in Q4 2025. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Heights Capital Management reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • Heights Capital Management sold 264,000 Crescent Biopharma shares in Q1 2026, an estimated $3.13M.
  • Heights Capital Management first reported a position in Crescent Biopharma in Q4 2025 and held it in 1 quarter.
  • Heights Capital Management's Crescent Biopharma position peaked at $3.13M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.